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Ugandan Adults on Antiretroviral Therapy: The COSTOP 
Trial Immunology Substudy
Jacqueline Kyosiimire-Lugemwa,1,  Zacchaeus Anywaine,1 Andrew Abaasa,1 Jonathan Levin,1,2 Ben Gombe,1 Kenneth Musinguzi,1 Pontiano Kaleebu,1 
Heiner Grosskurth,1,3 Paula Munderi,1,4 and Pietro Pala1
,
1Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda, 2School of Public Health, University of 
the Witwatersrand, Johannesburg, South Africa, 3Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom, and 4International 
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Background. Cotrimoxazole preventive therapy (CPT) in human immunodeficiency virus (HIV) infection is a World Health 
Organization–recommended standard of care in resource-limited settings, but the mechanism of CPT’s beneficial effects is unclear. 
The COSTOP trial (ISRCTN44723643) evaluated the noninferiority of discontinuing CPT in stabilized patients on antiretroviral 
therapy. The COSTOP immunology substudy was conducted on a subset of COSTOP participants randomized to continue CPT 
(n = 86) or discontinue CPT (placebo, n = 86) as daily treatment for 1 year.
Methods. We evaluated whether CPT reduces microbial translocation, indicated by the presence of bacterial lipopolysaccharide 
(LPS) and LPS control factors such as soluble CD14 (sCD14) and endotoxin core antibody (EndoCAb immunoglobulin M [IgM]) 
in plasma. Intestinal barrier damage as indicated by plasma intestinal fatty acid binding protein (IFABP), T-cell activation, and the 
inflammatory markers C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) were also evaluated.
Results. We found no significant change in markers of microbial translocation (LPS, IFABP, sCD14, and T-cell activation), with 
decreased EndoCAb IgM. There was significant increase in inflammation markers (CRP and IL-6) after stopping CPT compared to 
those who continued CPT.
Conclusions. These results add to the evidence of immunological benefits of CPT among HIV-infected populations in resource-
limited settings. However, no evidence of reducing microbial translocation was observed.
Keywords.  HIV-1; cotrimoxazole preventive therapy; inflammation; microbial translocation; immune activation; ART.
Cotrimoxazole preventive therapy (CPT) reduces morbidity and 
mortality in people with untreated human immunodeficiency 
virus (HIV) infection [1, 2] and in those on antiretroviral therapy 
(ART) [3, 4]. The mechanism underlying this benefit of CPT 
remains unclear. Cotrimoxazole is a combination of sulfamethox-
azole and trimethoprim with a broad spectrum of activity against 
bacteria as well as activity against Plasmodium falciparum (ma-
laria) due to the sulfamethoxazole component [5]. CPT might 
therefore act by causing a reduction in intercurrent infections. 
However, the benefit of CPT has been demonstrated in the pres-
ence of a high prevalence of antimicrobial resistance to CPT, and 
CPT has furthermore been associated with a benefit in infections 
caused by pathogens against which CPT is not known to have bi-
ological activity such as Mycobacterium tuberculosis, some other 
bacteria, and helminths [6–9]. One possible mechanism could be 
a nonspecific lowering of the bacterial load in the gastrointestinal 
tract or limiting damage to the mucosal epithelium, resulting in 
lower concentrations of microbial products crossing the intestinal 
mucosal barrier and consequent effect on reducing immune acti-
vation and inflammation.
HIV type 1 infection depletes the gut-associated CD4 T cells 
and damages the ability of the gut mucosal barrier to exclude 
microbial products present in the lumen from entering the 
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bloodstream [10]. Once in the bloodstream, lipopolysaccha-
ride (LPS) derived from gram-negative bacteria endotoxin and 
fungal products is captured by the LPS binding protein, which 
carries it to the CD14 receptor [11] on the membrane of mono-
cytes, neutrophils, epithelial cells, and dendritic cells. CD14 
brings LPS into contact with Toll-like receptor 4 (TLR4), stimu-
lating activation of the innate immune system either directly or 
in synergy with TREM-1 (triggering receptor expressed on my-
eloid cells 1) [12]. Thus, bacterial LPS contributes to systemic 
inflammation, raising levels of circulating C-reactive protein 
(CRP), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), 
and other cytokine/chemokines. Alternative mechanisms used 
to control LPS include host generation of natural antibodies 
against the endotoxin core (EndoCAb). These antibodies form 
complexes with circulating LPS and can become depleted from 
the plasma in the process [13]. The imbalance between LPS and 
endotoxin core antibodies may contribute to the general im-
mune activation of T cells [14] and the inflammation that char-
acterizes chronic HIV infection and which is associated with 
loss of CD4 cells and progression to AIDS [10].
In a cohort study of HIV-uninfected subjects from Entebbe, 
Uganda, baseline levels of inflammatory cytokines were found 
to be more elevated than in a cohort based in Lausanne, pre-
sumably because of higher exposure to environmental infec-
tions [15]. We hypothesized that in epidemiological contexts 
such as that prevailing in Uganda, CPT reduces levels of un-
specified bacterial infections, including levels of intestinal 
bacteria, and therefore the risk of intestinal microbial transloca-
tion. We evaluated whether CPT discontinuation is associated 
with increased microbial translocation, immune activation, and 
elevated levels of inflammatory markers.
MATERIALS AND METHODS
Study Design
The COSTOP trial (Safety of discontinuing cotrimoxaxole 
prophylaxis among human immunodeficiency virus 
(HIV) infected adults in Uganda: a randomised controlled 
trial,  ISRCTN44723643) was a randomized, double-blind, 
placebo-controlled noninferiority trial among 2180 HIV-
infected and stabilized patients on ART with CD4 counts ≥250 
cells/μL [16]. Findings of this trial showed that continued CPT 
significantly reduced the risk of severe bacterial infections and 
protected against malaria, whereas discontinuing CPT reduced 
hematological adverse events [17]. Within the COSTOP trial, 
the COSTOP immunology substudy was conducted on a subset 
of 172 COSTOP study participants, independently randomized 
and recruited toward the end of the trial’s enrollment phase. 
Like all other volunteers in the COSTOP trial, participants for 
the immunology study were randomly assigned to 1 of 2 study 
arms: 1 arm (n = 86) continued with CPT, and the other arm 
(n = 86) discontinued CPT and was given placebo. Blood sam-
ples were collected at baseline and at 3, 6, and 12 months.
Study Settings and Participants
The COSTOP immunology study was conducted at the Masaka 
Regional Referral Hospital (MRRH). Study participants were 
adult male and female HIV-infected Ugandans enrolled at 4 out-
patient HIV care clinics located near or within MRRH. The hos-
pital serves a periurban and rural population. All patients were 
stable on ART and at enrollment had CD4 counts of ≥250 cells/µL 
and had been taking CPT as standard of care for at least 6 months. 
Patients were excluded if they had CPT hypersensitivity, had an 
acute febrile illness, were in the first trimester of pregnancy, or 
had a grade 3 or 4 anemia, neutropenia, or thrombocytopenia.
Ethical approvals were obtained from the Uganda Virus 
Research Institute Research and Ethics Committee, the 
Ugandan National Council for Science and Technology, and the 
Uganda National Drug Authority. All participants gave written 
informed consent. Illiterate participants indicated their consent 
by thumbprint in the presence of an impartial literate witness.
Laboratory Investigations
LPS was considered as a marker of microbial translocation; in-
testinal fatty acid binding protein (IFABP) as a marker of in-
testinal barrier damage; soluble CD14 (sCD14) as a marker of 
monocyte activation or response to LPS; expression of HLA-DR 
and CD38 as markers of CD4 and CD8 T-cell activation; and 
anti-endotoxin core antibodies (EndoCAb immunoglobulin M 
[IgM]) as a marker of control of circulating LPS. We also as-
sessed IL-6, TNF-α, and CRP as markers of inflammation.
Ethylenediaminetetraacetic acid (EDTA) and heparin 
anticoagulated whole blood samples were collected at baseline 
and at 3, 6, and 12 months. Plasma was separated from whole 
blood, aliquoted, and stored at –80°C for later batch measure-
ment of plasma markers of microbial translocation and inflam-
mation. Sterile endotoxin-free tubes were used.
Microbial Translocation
LPS levels in plasma were measured with the limulus 
amoebocyte lysate (LAL)–based test with Endosafe portable 
test system (PTS) cartridges (catalog number PTS200005F; 
range, 0.5–0.005 EU/mL) for endotoxin microbial detection 
(Charles River) and read using an Endosafe PTS reader (Charles 
River). LPS levels were reported as endotoxin units (EU)/mL. 
Heparinized plasma was diluted 1:50 with LAL reagent water 
(LRW) to dilute any inhibitors. The diluted plasma was heated 
at 80°C for 10 minutes and LPS levels were measured using the 
Endosafe PTS endotoxin method, which included an internal 
control with a known endotoxin spike to correct the effect of 
any residual inhibitors. The negative control was LRW and the 
external positive control was a reference standard endotoxin 
(Charles River).
T-Cell Activation
Fresh EDTA whole blood samples (500 μL) were stained with 
antibodies CD3-QD655 (clone S4.1, Invitrogen), CD4-QD605 
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(clone S3.5, Invitrogen), CD8-PECy7 (clone 3B5, BD 
Biosciences), HLA-DR-FITC (clone G46-6, BD Biosciences), 
and CD38-APC (clone HIT2, BD Biosciences). CD14-Pacific 
blue (clone TÜK4) and CD19-Pacific blue (clone SJ25-C1) from 
Invitrogen were used to exclude monocytes and B cells. Stained 
cells were acquired on an 18-color LSR II flow cytometer (BD 
Immunocytometry Systems) and analyzed using FlowJo soft-
ware. The gating strategy (Supplementary Figure 2) was to 
gate on lymphocytes in the scatterplot, then singlets, then live 
CD3+ and CD14– and CD19– cells. From the CD3+ cell popula-
tion, CD4+ and CD8+ cell populations were selected. Activation 
was measured as percentage of CD38+HLA-DR+CD8+ or 
CD38+HLA-DR+CD4+ T cells.
Inflammation, sCD14, Epithelial Intestinal Damage, and Anti-
endotoxin Core Antibodies
Enzyme-linked immunosorbent assays (ELISAs) were per-
formed on stored plasma to determine the presence and levels of 
sCD14 (catalog number DC140; range, 250–16 000 pg/mL), IL-6 
(catalog number S6050; range, 1.56–100 pg/mL), TNF-α (cat-
alog number SSTA00C; range, 3.9–250 pg/mL), CRP (catalog 
number SCRP00; range, 0.78–50 ng/mL) (all from Quantikine 
immunoassays, R&D Systems Europe Ltd); IFABP (catalog 
number HK406-02; range, 47–3000 pg/mL), and EndoCAb (cat-
alog number HK-504-IgM; range, 0.05–3.5 MMU/mL) (Hycult 
Biotech). Absorbance values were read using the BioTek U Quant 
microplate reader (catalog number 285179), and Gen5 software 
was used to interpret plate readings. Standard operating pro-
cedures were designed for each of these assays (according to the 
manufacturer’s recommendations) and validity of the results in-
cluded assessing the R2 of each standard curve (>0.9) and intra-
assay/interassay validation %coefficient of variation of ≤ 15.
Statistical Methods
The sample size of 86 subjects per arm was determined based on 
comparing the primary outcome of LPS at 12 months between 
subjects who would continue CPT and subjects who would stop 
CPT at enrollment (ie, would take placebo). Assumptions were 
based on an earlier study comparing long-term nonprogressors 
(LTNPs) to rapid progressors, where it was found that the mean 
LPS levels differed between these 2 groups with a mean of 665 
pg/mL in the LTNP group and a mean of 757 pg/mL in the 
rapid progressor group (P = .0001), with a pooled within-group 
standard deviation (SD) of 54.6 pg/mL (J. Kyosiimire-Lugemwa, 
unpublished data). In the main COSTOP trial, all subjects had 
been on CPT and ART before enrollment, and due to the ran-
domization we assumed that the 2 arms were likely to be very 
similar at baseline with respect to the risk of intestinal micro-
bial translocation. It was therefore also likely that the difference 
in LPS levels at 12 months after CPT cessation would be smaller 
than that observed in the study of LTNPs and rapid progressors. 
Therefore, a sample size of 76 subjects per arm would have 80% 
power to detect as statistically significant at the 5% level a true 
mean difference of 25 pg/mL between subjects who continued 
CPT and those who stopped CPT for 12  months, assuming a 
pooled within-group SD of 55 pg/mL in LPS. For purposes of 
comparison of LPS units between the LTNP study mentioned 
above and the current study, 100 pg/mL is equivalent to 1 EU/mL; 
thus, 25 pg/mL is equivalent to 0.25 EU/mL. With the assump-
tion of smaller difference in LPS levels at 12 months, the sample 
size of 76 subjects per arm formed the sample size for the primary 
outcome investigated in the substudy. However, to cater for loss to 
follow-up of up to 10 patients, the sample size was increased to 86 
patients per arm. Furthermore, this sample size would also pro-
vide adequate power for investigation of the secondary outcomes.
LPS and all ELISA data were transcribed from the reader 
output into Excel spreadsheets; flow cytometry standard files 
from DiVA were analyzed with FlowJo; and cell frequencies 
were tabulated into Excel spreadsheets. Data were cleaned 
and analyzed using Stata 14 software (StataCorp). Participant 
baseline sociodemographics and clinical characteristics were 
summarized by trial arm using frequencies and percentages 
for categorical variables, and mean and SD or median and in-
terquartile range for continuous variables. The analysis was by 
intention to treat. We displayed the geometric mean markers 
by trial arm and over the follow-up time using line graphs and 
estimated the trend P value in each plot using a linear regres-
sion model controlling for the baseline value of each marker. 
Because the concentrations of LPS showed skewed distribu-
tions with 111 patients (59 cotrimoxazole and 52 placebo) 
having values below the minimum quantification threshold, a 
constant was added to each marker value before transforma-
tion on the natural logarithmic scale and subsequent analysis. 
Frequencies of activated CD4 and CD8 T cells were not trans-
formed. We compared the means of markers between subjects 
in the 2 trial arms at baseline and at 3, 6, and 12 months. Linear 
mixed models for longitudinal data were fitted for each marker, 
using the values at baseline, month 3, month 6, and month 12, 
with random terms for subject and random slopes over time, 
to compare the average slope over time in the 2 trial arms. The 
linear mixed models were fitted, first without a time interaction 
term and then including a time interaction term. Relationships 
between markers were evaluated by Spearman rank correlation 
and with Bonferroni correction for multiple comparisons.
RESULTS
Between 2012 and 2014, we enrolled 172 volunteers into the im-
munology substudy conducted in Masaka. Volunteers were ran-
domized (1:1) to either continue CPT (n = 86) or to discontinue 
treatment (placebo, n  =  86) and were followed up for 1  year 
(Supplementary Figure 1). The baseline characteristics of the 2 arms 
are summarized in Table 1. Randomization achieved a balanced 
baseline distribution between trial arms with regards to partici-
pants’ age, sex, sociodemographic and physical characteristics, stage 
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Table 1. Baseline Characteristics of the Study Participants by Trial Arm (N = 172)
Variable CPT (n = 86) Placebo (n = 86)
CD4 stratum   
 <500 cells/μL 41 (47.7) 42 (48.8)
 ≥500 cells/μL 45 (52.3) 44 (51.2)
CD4 count at randomization, cells/μL   
 Median (IQR) 534 (418–706) 537 (432–746)
 250–349 5 (5.8) 6 (7.0)
 350–499 36 (41.9) 36 (41.9)
 ≥500 45 (52.3) 44 (51.1)
Sex   
 Male 18 (20.9) 24 (27.9)
 Female 68 (79.1) 62 (72.1)
Age, y   
 Mean (SD) 41.4 (9.1) 42.3 (10.4)
 Median (IQR) 41 (36–47) 43 (34–50)
Weight, kg, mean (SD) 57.2 (10.3) 60.3 (11.3)
BMI, kg/m2, mean (SD) 22.5 (3.7) 23.4 (4.4)
WHO stage   
 I 9 (10.5) 5 (5.8)
 II 22 (25.6) 22 (25.6)
 III 51 (59.3) 54 (62.8)
 IV 4 (4.6) 5 (5.8)
Educational level   
 None 6 (7.0) 9 (10.5)
 Primary 60 (69.8) 59 (68.6)
 Secondary 20 (23.2) 16 (18.6)
 University/vocational 0 (0.0) 2 (2.3)
Marital status   
 Married/cohabiting 35 (40.7) 31 (36.1)
 Separated/divorced 47 (54.6) 50 (58.1)
 Single, never married 4 (4.7) 5 (5.8)
HIV status disclosure to partner   
 Yes 43 (50.0) 42 (48.8)
 No 3 (3.5) 4 (4.7)
 Unspecified 40 (46.5) 40 (46.5)
Months on ART, median (IQR) 50 (25–80) 43 (17–73)
Initial ART regimen   
 AZT/3TC/NVP 37 (43.0) 40 (46.5)
 AZT/3TC/EFV 9 (10.5) 5 (5.8)
 d4T/3TC/NVP 19 (22.1) 15 (17.4)
 d4T/3TC/EFV 1 (1.2) 1 (1.2)
 TDF/3TC (FTC)/NVP 15 (17.4) 16 (18.6)
 TDF/3TC (FTC)/EFV 5 (5.8) 8 (9.3)
 Other 0 (0.0) 1 (1.2)
Current ART regimen   
 AZT/3TC/NVP 45 (52.3) 44 (51.2)
 AZT/3TC/EFV 12 (14.0) 8 (9.3)
 TDF/3TC (FTC)/NVP 19 (22.1) 26 (30.2)
 TDF/3TC (FTC)/EFV 7 (8.1) 8 (9.3)
 Any PI 3 (3.5) 0 (0.0)
Any ART switch prior to enrollment   
 Yes 35 (40.7) 25 (29.1)
 No 51 (59.3) 61 (70.9)
Last missed ARVs   
 Last week 0 (0.0) 2 (2.3)
 1–4 wk ago 5 (5.8) 2 (2.3)
 1–3 mo ago 2 (2.3) 2 (2.3)
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of HIV infection, and current and past treatment regimens (Table 
1). During the study, only 4 cases of malaria occurred (2 in each 
arm). Retention was good, with 162 (94.2%) volunteers returning 
for their final month 12 study visit (80 and 82 in the CPT and pla-
cebo arms, respectively; Supplementary Figure 1). The numbers of 
study participants and their samples analyzed for each biomarker 
(from baseline to 12 months) are shown in Supplementary Table 1.
Plasma LPS Levels After CPT Discontinuation
Overall, there was no significant difference in plasma LPS levels be-
tween the 2 arms (Tables 2 and 3). We observed a modest decline 
in LPS levels from baseline to month 12 in both arms (Figure 1). 
Furthermore, stopping CPT increased LPS by a mean of approxi-
mately 0.03 EU/mL and 0.07 EU/mL in the model fitted without time 
interaction and the model with time interaction, respectively (Table 3), 
though this was not statistically significant. LPS did not significantly 
correlate with any other markers (Figure 2). The plasma inflammatory 
markers IL-6, CRP, and TNF-α increased after CPT was stopped.
At baseline, the means (reverse log transformed) of all sol-
uble markers were similar in the 2 arms except CRP, which 
showed a statistically significant difference in the mean between 
the arms. We observed a statistically significant difference in the 
mean level of IL-6 and CRP (P = .001 for both) at 3 months be-
tween the study arms. This was lost at 6 months and regained 
at 12 months for CRP and IL-6 (P = .045 and P = .023, respec-
tively; Table 2). Further analysis with linear mixed models 
showed that TNF-α, IL-6, and CRP levels significantly increased 
over time in the placebo arm (P = .045, P = .006, and P <.001, 
respectively) (Table 3). No significant differences between arms 
were observed for sCD14, IFABP, and CD4 activation markers. 
The frequency of activated CD8 T cells was higher (P =  .023) 
in the placebo arm at 6 months (Table 3). The difference in the 
means between the 2 arms showed a similar pattern for TNF-α, 
IL-6, and CRP level from baseline to 12 months with significant 
rise of IL-6 and CRP in the placebo arm (P < .001 and P < .001, 
respectively; Figure 1). There was a trend toward a reduction of 
IgM endotoxin core antibody in the placebo arm compared to 
the CPT arm (P = .01; Figure 1). The largest difference in CRP, 
IL-6, and TNF-α levels between the CPT and placebo arms was 
observed at 3 months (Figure 1).
Variable CPT (n = 86) Placebo (n = 86)
 >3 mo ago 4 (4.6) 4 (4.6)
 Never 75 (87.2) 76 (88.4)
Missed CPT in last month   
 Yes 29 (33.7) 19 (22.1)
 No 57 (66.3) 67 (77.9)
Sleeps under a mosquito net   
 Yes 43 (50.0) 41 (47.7)
 No 43 (50.0) 45 (52.3)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; ARV, antiretroviral; AZT, azidothymidine; BMI, body mass index; CPT, cotrimoxazole preventive therapy; d4T, stavudine; EFV, 
efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus; IQR, interquartile range; NVP, nevirapine; PI, protease inhibitor; SD, standard deviation; TDF, tenofovir disoproxil fumarate; 
WHO, World Health Organization.
Table 1. Continued
Table 2. Mean Levels of Markers at Baseline and 3, 6, and 12 Months by Treatment Arm
Marker
Baseline (Month 0) Month 3 Month 6 Month 12
CPT Placebo P Value CPT Placebo P Value CPT Placebo P Value CPT Placebo P Value
LPS, EU/mL 1.22a 0.28 .087 0.20 0.22 .397 1.21 1.16 .232 1.17 1.21 .261
TNF-α, pg/mL 2.18 2.10 .792 2.20 2.77 .088 2.97 3.56 .219 2.83 3.56 .119
sCD14, pg/mL 1 595 982 1 599 178 .850 1 672 784 1 776 223 .168 1 830 318 1 758 550 .310 1 953 240 1 966 961 .876
IL-6, pg/mL 2.74 3.04 .205 2.61 3.96 .001 2.71 3.26 .082 2.88 3.45 .045
EndoCAb IgM 49.40 46.06 .455 51.94 45.60 .103 47.94 43.82 .312 52.46 45.15 .109
IFABP, pg/mL 1118.79 1236.45 .268 1225.37 1230.28 .918 1155.17 1151.71 0.977 1118.79 1176.15 .567
CRP, ng/mL 1088.98 1649.12 .036 1327.43 2418.74 .001 1198.71 1694.26 0.108 1176.15 1872.44 .023
CD4+ CD38+ HLA-DR+, %b 0.22 0.25 .559 0.22 0.26 .330 0.21 0.23 0.568 0.56 0.57 .836
CD8+ CD38+ HLA-DR+, %b 0.37 0.45 .399 0.42 0.43 .929 0.25 0.38 0.023 0.75 0.85 .508
P values of the  t test comparing CPT to placebo arm for each log-transformed marker at each month of follow-up. Values in bold are statistically significant.
Abbreviations: CPT, cotrimoxazole preventive therapy; CRP, C-reactive protein; EndoCAb, anti-endotoxin core antibody; IFABP, intestinal fatty acid binding protein; IgM, immunoglobulin M; 
IL-6, interleukin 6; LPS, lipopolysaccharide; sCD14, soluble CD14; TNF-α, tumor necrosis factor alpha.
aMean (reverse log transformed).
bMarker not transformed on logarithm scale and indicates activation levels.
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We further evaluated pairwise relationships between all 
markers by Spearman rank correlation. At baseline, a strong 
positive monotonic correlation was observed between activated 
CD4 and activated CD8 cell frequencies (r  =  0.78) and weak 
positive correlations between CRP and sCD14 (r = 0.38), CRP 
and IL-6 (r = 0.30), and IL-6 and activated CD4 and activated 
CD8 cell frequencies (r = 0.30 for both) (Figure 2A). After CPT 
discontinuation, the 2 arms had similar positive monotonic cor-
relations of activated CD4 and CD8 T-cell frequencies (r = 0.79 
for placebo and r = 0.78 for CPT), CRP and sCD14 (r = 0.30 for 
placebo and r = 0.36 for CPT), CRP and IL-6 (r = 0.54 for pla-
cebo and r = 0.33 for CPT), TNF-α and IL-6 (r = 0.20 for pla-
cebo and r = 0.30 for CPT), and a weak correlation of sCD14 and 
IL-6 (r = 0.26) and activated CD8 T-cell frequencies with TNF-α 
(r = 0.26), seen in participants in the placebo arm (Figure 2B).
DISCUSSION
This was a randomized double-blind controlled trial to test the 
effect of discontinuing CPT on microbial translocation and 
immune activation among adult Ugandans infected with HIV, 
clinically stable and on ART. We tested the hypothesis that CPT 
reduces microbial translocation from the gastrointestinal tract 
and thus we expected an increase in plasma LPS, inflammatory 
cytokines, and immune activation among HIV-infected indi-
viduals on ART when CPT was discontinued. We observed no 
difference in LPS between the arms from baseline to 12 months 
(primary outcome) and no significant correlation of LPS with 
any inflammatory marker. Markers for inflammation (IL-6 and 
CRP) and CD8 T-cell activation markers increased after CPT 
was stopped.
We observed increase in inflammation markers as early as 
3 months after discontinuing CPT. Our finding of similar levels 
of plasma LPS in the CPT as in the placebo arm suggests that 
microbial translocation is similar in both arms, leaving the 
question of what might be causing the increase of inflammatory 
markers in the placebo arm. A direct anti-inflammatory effect 
of cotrimoxazole in vitro, suppressing the TNF-α and IL-6 re-
sponse to LPS or zymosan in whole blood or the release of 
IL-8 by Caco-2 epithelial cell lines treated with IL-1β, was 
shown recently by Bourke et  al [18]. Increased plasma IL-6, 
CRP, and TNF-α, but not sCD14, were observed after CPT 
discontinuation [18]. Alternatively, while microbial resistance 
to cotrimoxazole is widespread, cotrimoxazole might be al-
tering the composition of the intestinal microbiome. In the 
Anti-Retroviral Research for Watoto  (ARROW) study, sup-
pression of abundance and function of gut-resident strepto-
cocci (not LPS producers) were described in Zimbabwean 
HIV-infected children continuing CPT, while global effects 
on gut microbiome were not observed and LPS-producing 
Enterobacteriaceae were not affected or even increased [18]. 
Fecal myeloperoxidase, a marker of intestinal inflammation, 
was lower in children continuing CPT [18]. Thus, studies in 
children and adults show anti-inflammatory effects of CPT 
not involving changes in plasma endotoxin. These mechan-
isms warrant further investigation.
Plasma sCD14, which binds LPS and has been shown to 
have a modulatory effect on the immune system [11, 19, 20], 
was not different between study arms. We observed a weak 
positive correlation of IL-6, CRP, and sCD14 in both arms, 
suggesting an involvement of sCD14 in the overall inflam-
matory response.
We observed a moderate effect of CPT on CD8 T-cell acti-
vation at 6 months. In both study arms, a rise in the activation 
markers CD4 and CD8 (T-cell activation) and sCD14 (mono-
cyte activation) levels between 6  months and 12  months was 
observed. This could indicate loss of adherence to ART in both 
arms and to CPT in the CPT continuation arm or a general 
effect of disease progression. We did not assess systemic drug 
concentrations of both ART and CPT in this study. While mi-
crobial translocation was shown to increase immune activation 
Table 3. Effect of Discontinuing Cotrimoxazole Preventive Therapy Analyzed by Fitting a Linear Mixed Model Without and Without Time Interaction
Model
LPS, EU/mL TNF-α, pg/mL sCD14, pg/mL IL-6, pg/mL
EndoCAb 
IgM, MMU/
mL IFABP, pg/mL CRP, ng/mL
CD4+ CD38+ 
HLA-DR+, %
CD8+ CD38+ 
HLA-DR+, %
Coef P Value Coef P Value Coef P Value Coef P Value Coef P Value Coef P Value Coef P Value Coef P Value Coef P Value
Without time interaction
 Stopping CPT 0.03 .082 0.66 .045 5405 .924 0.70 .006 –7.31 .100 42.67 .629 860.74 < .001 0.03 .331 0.08 .189
With time interaction
 Stopping CPT at M0 0.07 .060 0.04 .945 –15 626 .825 0.40 .342 –6.86 .193 49.44 .673 567.32 .070 0.03 .572 0.08 .448
 Stopping CPT at M3 –0.04 .410 1.16 .161 116 482 .087 0.94 .092 0.09 .984 40.93 .738 710.88 .044 0.01 .885 –0.06 .649
 Stopping CPT at M6 –0.08 .081 0.46 .580 –46 717 .495 –0.05 .936 2.70 .561 –97.13 .431 –69.35 .845 –0.01 .982 0.05 .700
 Stopping CPT at M12 –0.01 .791 0.86 .307 10 737 .876 0.26 .649 –4.61 .321 25.60 .835 519.28 .144 –0.02 .835 0.02 .901
Linear mixed models fitted with random terms for subject and random slopes over time. Values in bold are statistically significant.
Abbreviations: Coef, coefficient representing average slope over time between subjects who continue and those who stop cotrimoxazole preventive therapy; CPT, cotrimoxazole preventive 
therapy; CRP, C-reactive protein; EndoCAb, anti-endotoxin core antibody; IFABP, intestinal fatty acid binding protein; IgM, immunoglobulin M; IL-6, interleukin 6; LPS, lipopolysaccharide; M0, 
month 0; M3, month 3; M6, month 6; M12, month 12; sCD14, soluble CD14; TNF-α, tumor necrosis factor alpha.
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in cross-sectional studies in HIV-infected patients from the 
United States [11], studies in African populations did not show 
such association [21, 22].
Endotoxin core antibodies are antibodies to LPS. We ex-
pected higher levels of LPS in the placebo arm, and conse-
quently changes in EndoCAb IgM. Indeed, we observed a trend, 
sustained throughout the study, toward reduced IgM in the 
placebo arm, possibly showing increased consumption of IgM 
antibodies. Decrease in endotoxin core antibodies has been as-
sociated with increased endotoxin levels and increased inflam-
mation [23].
We found no change in IFABP levels. Two other studies 
have shown no change of IFABP levels following CPT and 
ART medication among HIV-infected individuals [24, 25]. 
Enterocyte damage happens early in HIV infection and has 
not been shown to be restored even with ART [25], which 
may be why we observed a generally high level of IFABP in 
all study participants.
The strengths of our study consist of its randomized, dou-
ble-blind, placebo-controlled design; the extended 1-year 
follow-up period with 4 standardized time points; and the 
broad battery of markers addressing the response to CPT 
discontinuation. The study has some limitations: We did not 
assess type I  interferons stimulated by LPS via the MyD88 
independent pathway. This could have given information 
on modulating effects in endotoxin tolerance. In addition, 
LAL-based assays quantify only unbound or free LPS, yet 
the LPS bound to lipoproteins is also biologically active and 
if not quantified, there is a possibility of masking the total 
LPS effect [26, 27]. The LAL-based assay has been shown 
to equally detect both the strongly endotoxic LPS and low 
or nonendotoxic forms of LPS [28]. We only used LPS as 
a marker of microbial translocation; however, analyzing 
blood 16S rDNA might have provided an alternative quanti-
tative and qualitative measure of bacterial translocation. We 
did not examine the intestinal microbiome itself.
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Figure 1. Trajectories of microbial translocation (lipopolysaccharide), T-cell immune activation, intestinal barrier damage, and inflammation markers from baseline to 3, 6, 
and 12 months. The plotted mean levels of markers were compared using geometric means; the P value in each plot refers to the linear regression model P value controlling 
for the baseline value of each marker. The dashed line shows the cotrimoxazole preventive therapy arm, complete black is the placebo arm, and the bars show the 95% 
confidence interval at each time point. Abbreviations: CI, confidence interval; CPT, cotrimoxazole preventive therapy; CRP, C-reactive protein; EndoCAb, anti-endotoxin core an-
tibody; IFABP, intestinal fatty acid binding protein; IgM, immunoglobulin M; IL-6, interleukin 6; LPS, lipopolysaccharide; sCD14, soluble CD14; TNF-α, tumor necrosis factor α.
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Increased levels of inflammatory markers can also be seen 
in HIV-uninfected individuals from Africa [15], and chronic 
inflammation has been associated with cardiovascular disease 
and mortality among HIV-infected adults and children on 
ART [29–31]. Plasma levels of the inflammatory markers IL-6 
and CRP are independently associated with mortality in HIV-
infected and uninfected adults [32–35] and in HIV-infected 
Ugandan children [30]. Although we could not confirm that 
CPT discontinuation was associated with microbial translo-
cation as reflected by plasma LPS, the mechanism by which 
CPT may reduce systemic inflammation in the presence of 
intestinal barrier damage might involve modulatory mechan-
isms of the MyD88 independent pathway and needs further 
investigation.
Our findings suggest that among HIV-infected individuals 
stabilized on ART and CPT, CPT discontinuation does not 
increase microbial translocation from the gut and suggest that 
a beneficial effect of CPT in lowering inflammatory markers 
and a moderate effect on T-cell activation. These results are im-
portant for the clinical management of HIV disease and should 
be considered when weighing the pros and cons of CPT in 
resource-restricted countries.
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